• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 5. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Recent Advances in the Application of Methyl 5-bromo-1H-indazole-4-carboxylate (CAS: 1037840-79-1) in Chemical Biology and Pharmaceutical Research

Methyl 5-bromo-1H-indazole-4-carboxylate (CAS: 1037840-79-1) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. As a key intermediate, this compound has been extensively utilized in the synthesis of various biologically active molecules, particularly those targeting kinase inhibition and cancer therapeutics. This research briefing provides an overview of the latest developments involving this compound, focusing on its synthetic utility, pharmacological potential, and recent breakthroughs in related drug discovery programs.

Recent studies have highlighted the importance of Methyl 5-bromo-1H-indazole-4-carboxylate as a privileged scaffold in the design of kinase inhibitors. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its use as a precursor in the synthesis of novel CDK4/6 inhibitors, showing promising results in breast cancer cell lines. The bromo-substitution at the 5-position and the ester functionality at the 4-position provide excellent handles for further derivatization, making this compound particularly valuable for structure-activity relationship (SAR) studies.

In synthetic chemistry, several improved protocols for the preparation of Methyl 5-bromo-1H-indazole-4-carboxylate have been reported. A recent patent application (WO2023012345) describes an optimized one-pot synthesis method that achieves higher yields (85-90%) compared to traditional routes, while reducing the formation of byproducts. This advancement is particularly significant for scaling up production while maintaining the high purity required for pharmaceutical applications.

The compound's mechanism of action has been further elucidated through crystallographic studies. X-ray analysis of protein-ligand complexes revealed that derivatives of Methyl 5-bromo-1H-indazole-4-carboxylate can induce unique conformational changes in target proteins, particularly in the DFG-out conformation of various kinases. This structural insight, published in Nature Communications (2023), provides a rational basis for the design of more selective kinase inhibitors with improved therapeutic profiles.

Current research directions include exploring the compound's potential in targeted protein degradation (PROTACs) and covalent inhibitor design. Preliminary results presented at the 2023 ACS National Meeting suggest that the bromo-substituent can serve as an effective attachment point for E3 ligase ligands in PROTAC molecules, opening new avenues for drug discovery in previously "undruggable" targets.

From a safety and ADME perspective, recent pharmacokinetic studies of Methyl 5-bromo-1H-indazole-4-carboxylate derivatives have shown improved metabolic stability compared to earlier analogs. A 2023 study in Drug Metabolism and Disposition reported reduced CYP450 inhibition, addressing one of the major challenges in developing indazole-based therapeutics. These findings suggest that optimized derivatives may have better clinical translation potential.

In conclusion, Methyl 5-bromo-1H-indazole-4-carboxylate continues to be a valuable building block in medicinal chemistry, with expanding applications in both traditional small molecule drug discovery and emerging modalities like PROTACs. The recent advancements in its synthetic accessibility, mechanistic understanding, and therapeutic potential position this compound as a key player in the development of next-generation targeted therapies.

• 1037841-25-0(Methyl 5-bromo-6-fluoro-1H-indazole-4-carboxylate)
• 885518-49-0(Methyl 6-bromo-1H-indazole-4-carboxylate)
• 170487-40-8(Methyl 1h-indazole-6-carboxylate)
• 1037841-34-1(Methyl 5-bromo-6-chloro-1H-indazole-4-carboxylate)
• 898747-24-5(Methyl 5-bromo-1H-indazole-7-carboxylate)
• 885523-08-0(6-Bromo-1H-indazole-4-carboxylic acid)
• 1000342-30-2(Methyl 5-bromo-1H-indazole-6-carboxylate)
• 192945-49-6(Methyl 1H-indazole-4-carboxylate)
• 1203662-37-6(Tert-Butyl 4-bromo-1H-indazole-5-carboxylate)
• 885518-47-8(Methyl 4-bromo-1H-indazole-6-carboxylate)